Health

STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:25 UTC.

Briefings

STAT+ reports that the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the Trump administration regarding a pilot Medicare drug pricing program called GLOBE. The industry argues the mandatory GLOBE program exceeds statutory authority, while voluntary agreements with Medicaid are acceptable. The administration plans to allow temporary sales of restricted peptides as new regulations are finalized, potentially enabling compounding pharmacies to dispense untested treatments. The Washington Post reports the plan timing remains unclear.

Key points

• PhRMA filed a lawsuit against the Trump administration over a pilot Medicare drug pricing program called GLOBE, asserting it exceeds statutory authority.
• The administration plans to allow temporary sales of restricted peptides as new regulations are finalized, potentially enabling compounding pharmacies to dispense untested treatments.

Context

STAT+ is a trade publication covering pharmaceutical industry news, specifically focusing on disputes between brand-name drug makers and the Trump administration regarding Medicare pricing policies and peptide regulations.

Limitations

The article provides limited background on the GLOBE program's specific impact, noting it is not expected to have much impact due to exemptions. The administration's final plans for the peptide sales have not yet been announced, meaning the timeline and scope remain uncertain.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 05:02:44 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiecpktpf3ql3sudwiwodd74wcjriubtff5naq2bccej4yooidtxyu